Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06285422 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
A Phase 1 study of Non-Hodgkin's Lymphoma and Large B-cell Lymphoma, sponsored by Sana Biotechnology.
- Active
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 3
- Study locations
NCT06285422 is a Phase 1 study of Non-Hodgkin's Lymphoma and Large B-cell Lymphoma that is active but no longer recruiting, run by Sana Biotechnology. The registered enrollment target is 6 participants, below the 222-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT06285422, a Phase 1 study of Non-Hodgkin's Lymphoma and Large B-cell Lymphoma, is active but no longer recruiting, sponsored by Sana Biotechnology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 3
- Study locations
Study Summary
SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
Conditions Studied
Interventions
- DRUG SC262
Study Locations (3)
Washington
- Swedish Cancer Institute - Seattle
- Fred Hutchinson Cancer Center - Seattle
Kansas
- The University of Kansas Hospital - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2024-04-18 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06285422
The ClinicalTrials.gov registry entry for NCT06285422 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 222-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (97% lower). The listed sponsor is Sana Biotechnology, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which SC262 is the first listed.
NCT06285422 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Washington, Kansas.
Frequently Asked Questions
What is clinical trial NCT06285422 about?
NCT06285422 is a clinical study titled "Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)". SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
What is the current status of trial NCT06285422?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2024-04-18. Estimated completion is 2029-03.
What conditions does trial NCT06285422 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma, Large B-cell Lymphoma.
What interventions are being tested in trial NCT06285422?
The interventions under investigation include: SC262 (DRUG).
Who is sponsoring clinical trial NCT06285422?
This trial is sponsored by Sana Biotechnology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06285422 being conducted?
This trial has 3 study locations across Kansas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
RECRUITING · Phase 1
-
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
RECRUITING · Phase 1
-
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
RECRUITING · Phase 1
-
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.